Pharmaceuticals, Biotechnology and Life Sciences
Steven H. Collis, the President and Chief Executive Officer (CEO) of AmerisourceBergen Corporation will succeed Richard C. Gozon as Chairman of the Board
Hikma’s Portuguese facility back into compliance with the US FDA.
The US Food and Drug Administration (FDA) has accepted Sandoz’s Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Neulasta (pegfilgrastim) – a recombinant human granulocyte colony-stimulating factor (G-CSF).
Sanofi has appointed Xavier Darcos as President of the Sanofi Espoir Foundation, who succeeds Jean-François Dehecq. Under Dehecq’s Presidency, According to the…
Mylan N.V. has launch Almotriptan Tablets USP, 6.25 mg and 12.5 mg, the generic version of Janssen Pharmaceutical’s AXERT in the U.S.…
Advaxis, a clinical-stage biotechnology company developing cancer immunotherapies, has received preliminary approval for a $1.8 million tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2015.
Amgen will present eight IMLYGIC (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck’s anti-PD-1 therapy, at the 12th International Congress of the Society for Melanoma Research …
Gilead Sciences, Inc. said Monday that its Phase 3 Study 115 evaluating Zydelig (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early.
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.